GGrantIndex
Sort

40,608 grants matching prostate cancer

GRANZYME B PET AS A NOVEL MEANS TO ASSESS T-CELL ACTIVATION IN RESPONSE TO 177LU-PSMA-617 PRIMING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

$685,497
Regents Of The University Of California, San Francisco, The · · FY2022 · Department of the Army

Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer

$685,408
Anna M Wu · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA

Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways

$685,245
Ira Daar · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion

$685,245
Ira Daar · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab

$685,217
Jason S Lewis · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens

$685,130
Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Maryland Prostate Cancer Case-Control Study

$685,102
Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

The Molecular Profile of Prostate Tumors in African-American Men

$685,102
Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

A Systems Biology Approach to the Development of Cancer Biomarkers

$685,047
Arul M Chinnaiyan · University Of Michigan At Ann Arbor · U01 · FY2012 · CA

Using Clinical Pharmacology Principles to Develop New Anticancer Therapies

$685,021
William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2017 · CA

Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs)

$684,995
Ramesh Narayanan · University Of Tennessee Health Sci Ctr · R01 · FY2021 · CA

Development/Clinical Validation Markers for Prostate Ca

$684,827
Alan W Partin · Johns Hopkins University · U01 · FY2007 · CA

Circulating metabolites as novel risk biomarkers for gastric cancer: a large multi-center prospective investigation

$684,688
Xiang Shu · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA

High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy

$684,659
Udai S Kammula · Basic Sciences · Z01 · FY2007 · CA

CLINICAL TRANSLATION OF HYPERPOLARIZED 13C-UREA FOR CANCER MR MOLECULAR IMAGING

$684,591
John Kurhanewicz · University Of California, San Francisco · R01 · FY2017 · CA

Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy

$684,576
Kosj Yamoah · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2022 · CA

Biochemical and cellular analysis of regulatory T cells reactive to a natural self antigen

$684,530
Erin June Adams · University Of Chicago · R01 · FY2017 · AI

Biochemical and cellular analysis of regulatory T cells reactive to a natural self antigen

$684,530
Erin June Adams · University Of Chicago · R01 · FY2016 · AI

Growth Regulation Section

$684,396
Ira Pastan · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes

$684,131
Stephen Jay Freedland · Cedars-Sinai Medical Center · R01 · FY2025 · CA

Multimodal MR-PET Machine Learning Approaches for Primary Prostate Cancer Characterization

$684,119
Ciprian Catana · Massachusetts General Hospital · R01 · FY2018 · CA

Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients

$684,107
Sheung Chee Thomas Ng · Massachusetts General Hospital · R01 · FY2025 · CA

Macrocycle inhibition of beta-catenin mediated transcription in prostate cancer

$684,075
Susan K. Logan · New York University School Of Medicine · R01 · FY2025 · CA

High-Resolution Breast MRI at 3.0T

$684,033
Brian Andrew Hargreaves · Stanford University · R01 · FY2022 · EB

The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab

$684,004
Jason S Lewis · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA